Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTERA
2021-004530-11Phase 3Completed
- Sponsor
- Altos Biologics
- Start
- Dec 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in exudative macular degeneration comparing ALT-L9 with Eylea (2 arms). Primary endpoint: Change from baseline in best corrected visual acuity at Week 8. Started Dec 2021; status: completed.
02
Drugs
afliberceptalt-l9
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2021-004530-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004530-11.